(MedPage Today) — The FDA expanded the indication of the long-acting growth hormone somapacitan (Sogroya) to include very young children with idiopathic short stature, short stature born small for gestational age, or growth failure associated…
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/120143
Author :
Publish date : 2026-03-03 19:42:00
Copyright for syndicated content belongs to the linked Source.
